Abstract

Acute kidney injury (AKI) has gained significant attention following patient safety alerts about the increased risk of harm to patients, including increased mortality and hospitalization. Common causes of AKI include hypovolaemia, nephrotoxic medications, ischaemia and acute glomerulonephritis, although in reality it may be undetermined or multifactorial. A period of inflammation either as a contributor to the kidney injury or resulting from the injury is almost universally seen. This article was compiled following a workshop exploring the interplay between injury and inflammation. AKI is characterized by some degree of renal cell death through either apoptosis or necrosis, together with a strong inflammatory response. Studies interrogating the resolution of renal inflammation identify a whole range of molecules that are upregulated and confirm that the kidneys are able to intrinsically regenerate after an episode of AKI, provided the threshold of damage is not too high. Kidneys are unable to generate new nephrons, and dysfunctional or repeated episodes will lead to further nephron loss that is ultimately associated with the development of renal fibrosis and chronic kidney disease (CKD). The AKI to CKD transition is a complex process mainly facilitated by maladaptive repair mechanisms. Early biomarkers mapping out this process would allow a personalized approach to identifying patients with AKI who are at high risk of developing fibrosis and subsequent CKD. This review article highlights this process and explains how laboratory models of renal inflammation and injury assist with understanding the underlying disease process and allow interrogation of medications aimed at targeting the mechanistic interplay.

Details

Title
The complex interplay between kidney injury and inflammation
Author
McWilliam, Stephen J 1 ; Wright, Rachael D 2 ; Welsh, Gavin I 3 ; Tuffin, Jack 3 ; Budge, Kelly L 2 ; Swan, Laura 4 ; Wilm, Thomas 4 ; Ioana-Roxana Martinas 4 ; Littlewood, James 5 ; Oni, Louise 6 

 Department of Paediatric Pharmacology, Alder Hey Children’s Hospital, Liverpool, UK; Department of Women and Children’s Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK 
 Department of Women and Children’s Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK 
 Bristol Renal, Bristol Medical School, University of Bristol, Bristol, UK 
 Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK 
 Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK; Department of Nephrology, Royal Liverpool University Hospital, Liverpool, UK 
 Department of Women and Children’s Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK; Department of Paediatric Nephrology, Alder Hey Children’s NHS Foundation Trust Hospital, Liverpool, UK 
Pages
780-788
Publication year
2021
Publication date
Mar 2021
Publisher
Oxford University Press
ISSN
20488505
e-ISSN
20488513
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3169589244
Copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.